Briefing: eMERGE Genomic Risk Assessment and Management Network – Coordinating Center

Research Focus

This is a single-source cooperative agreement (U01) to continue coordinating the eMERGE (Electronic Medical Records and Genomics) Network, which integrates genomic risk assessment with clinical outcomes in approximately 25,000 patients. The network combines polygenic risk scores (PRS), monogenic risk variants, family history, and clinical data into genomic-informed risk assessments (GIRA) for 10 common diseases (breast cancer, prostate cancer, diabetes, hypercholesterolemia, asthma, and others). The coordinating center will extend patient follow-up from 1 year to a minimum of 4 years, measuring longer-term adherence to and outcomes of GIRA-based preventative recommendations among clinicians and patients. Research will assess how genomic risk information influences healthcare utilization, behavior change, clinician workload, and health outcomes across diverse populations. The network will leverage electronic phenotypes (e-phenotypes), natural language processing (NLP), and the OMOP common data model to extract outcome data from electronic medical records (EMRs), with results shared through community resources like AnVIL and ClinVar.

At a Glance

• Who can apply: Vanderbilt University Medical Center (single-source award; current eMERGE coordinating center under RFA-HG-19-015)
• Funding & duration: Not stated; project extends through April 2030
• Award mechanism: U01 Clinical Trial Required cooperative agreement
• Key dates: Application due March 6, 2026; scientific merit review July 2026; advisory council review October 2026; earliest start December 2026
• Best fit for: Health services research, implementation science, and genomic medicine teams studying clinical integration of PRS/GIRA, patient-clinician decision-making, and health equity across ancestry groups